# Clinical Trial of AGB101 for Mild Cognitive Impairment

> **NCT05986721** · PHASE2 · WITHDRAWN · sponsor: **AgeneBio**

## Conditions studied

- Mild Cognitive Impairment
- Prodromal Alzheimer's Disease

## Interventions

- **DRUG:** AGB101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05986721
- **Lead sponsor:** AgeneBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-03
- **Primary completion:** 2028-07
- **Final completion:** 2028-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986721, "Clinical Trial of AGB101 for Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05986721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*